Radioimmunotherapy-Based Conditioning Regimen Prior to Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Eskian, Mahsa; Khorasanizadeh, MirHojjat; Isidori, Alessandro; Rezaei, Nima

doi:10.2217/ijh-2017-0025

Cited by 5 publications

(2 citation statements)

References 48 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reasons for the lower effect on solid tumors may include poor tissue perfusion of solid tumors, resulting in poor anti-tumor efficacy, and the tendency of tumor cells to develop radiotherapy resistance 117 . In addition, IV RIT exerts hematologic toxicity due to its long blood circulation time and the possibility of inducing hematologic malignancies 118 , 119 . It should also be emphasized that RIT relies on highly specific targeted antibodies.…”

Section: Immune-related Therapy In Pmpmentioning

confidence: 99%

Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei

Zhao,

Wei,

et al. 2024

Cancer Biol Med

View full text Add to dashboard Cite

Pseudomyxoma peritonei (PMP) is an indolent malignant syndrome. The standard treatment for PMP is cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy (CRS + HIPEC). However, the high recurrence rate and latent clinical symptoms and signs are major obstacles to further improving clinical outcomes. Moreover, patients in advanced stages receive little benefit from CRS + HIPEC due to widespread intraperitoneal metastases. Another challenge in PMP treatment involves the progressive sclerosis of PMP cell-secreted mucus, which is often increased due to activating mutations in the gene coding for guanine nucleotide-binding protein alpha subunit (GNAS). Consequently, the development of other PMP therapies is urgently needed. Several immune-related therapies have shown promise, including the use of bacterium-derived non-specific immunogenic agents, radio-immunotherapeutic agents, and tumor cell-derived neoantigens, but a well-recognized immunotherapy has not been established. In this review the roles of GNAS mutations in the promotion of mucin secretion and disease development are discussed. In addition, the immunologic features of the PMP microenvironment and immune-associated treatments are discussed to summarize the current understanding of key features of the disease and to facilitate the development of immunotherapies.

show abstract

Section: Immune-related Therapy In Pmpmentioning

confidence: 99%

Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei

Zhao,

Wei,

et al. 2024

Cancer Biol Med

View full text Add to dashboard Cite

show abstract

“…Additions to standard conditioning regimens are undergoing evaluation to deepen consolidation responses and reduce the risk of relapse after autoHCT with a focus on cellular and immune-based therapies. Radioimmunotherapies, using an antibody labeled radionuclide to target the radiation's effects, like 131 Iodine-tositumumab and 90 Yttrium-ibritumomab tiuxetan have been studied but are not commonly used due to the complexity of administration, delayed engraftment, and prolonged cytopenias (74). An ongoing phase 2 trial evaluating a novel anti-CD25 radioimmunotherapy ( 90 Yttriumbasiliximab) combined with BEAM conditioning (aTAC-BEAM) is ongoing (NCT04871607).…”

Section: Alternative and Adjunctive Conditioning Strategiesmentioning

confidence: 99%

The role of transplantation in Hodgkin lymphoma

Maranzano

Mead

2023

Front. Oncol.

View full text Add to dashboard Cite

Despite the success of frontline anthracycline-based chemotherapy for classical Hodgkin Lymphoma (cHL), approximately 15% of patients do not achieve an adequate response and require further therapy. For transplant-eligible patients, additional treatment followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation (autoHCT) provides a durable response in 50% of patients. The most refractory patients, including those requiring multiple lines of therapy to achieve a response or those relapsing after an autoHCT, may achieve long-term survival with allogeneic hematopoietic stem cell transplant (alloHCT). Contemporary salvage regimens used as a bridge to transplant have expanded to include not only non-cross resistant chemotherapy, but also brentuximab vedotin (BV) and checkpoint inhibitors (CPI). As the management of relapsed/refractory (R/R) cHL evolves with the introduction of novel agents, so too does the role of transplantation. The paradigm of chemosensitivity as a predictor for autoHCT efficacy is being challenged by favorable post- autoHCT outcomes in heavily pre-treated CPI-exposed patients. Contemporary supportive care measures, validated comorbidity assessments, and an increased donor pool with haploidentical donors have broadened the application of transplantation to an increasingly older and diverse patient population. Despite the introduction of increasingly effective treatment options for R/R cHL, transplantation continues to play an important role in the management of these patients. In this review, we explore the impact of salvage therapy on autoHCT, conditioning regimens, maintenance therapy and the diminishing role of alloHCT for patients with cHL.

show abstract